Pfizer Raises Estimates for COVID Vax Sales by $2B

Pfizer Raises Estimates for COVID Vax Sales by $2B

The company maintained its full-year sales forecast for COVID-19 pill Paxlovid at $22 billion.

Pfizer and Moderna have rolled out an Omicron-tailored booster dose in Europe and the United States.

It reported third-quarter sales of $22.60 billion, beating the average analyst estimate of $21.04 billion, according to IBES data from Refinitiv .

Pfizer Raises Estimates for COVID Vax Sales by $2B.

The company maintained its full-year sales forecast for COVID-19 pill Paxlovid at $22 billion.

Pfizer and Moderna have rolled out an Omicron-tailored booster dose in Europe and the United States.

It reported third-quarter sales of $22.60 billion, beating the average analyst estimate of $21.04 billion, according to IBES data from Refinitiv.